Canada: Food, Drugs, Healthcare, Life Sciences

The Federal Court's recent decision in Alexion Pharmaceuticals, Inc. v. Amgen Canada Inc. (2025 FC 754) offers important guidance on the use of prior art for anticipation arguments in patent validity.

In the first half of 2025, the Rx IP Update team reported on a number of developments in Canadian life sciences IP and regulatory law. Below are our top stories.

The Patented Medicine Prices Review Board (PMPRB) is a Canadian federal agency that regulates the prices of patented medicines in Canada.

In the first half of 2025, the Rx IP Update team reported on a number of developments in Canadian life sciences IP and regulatory law. Below are our top stories.

The Patented Medicine Prices Review Board (PMPRB) is a Canadian federal agency that regulates the prices of patented medicines in Canada.

On June 30, 2025, the PMPRB published final non-binding guidelines (Guidelines) titled Guidelines for PMPRB Staff: Administrative Process for Excessive Price Hearing Recommendation.

On July 2, 2025, the Director of Integrated Community Health Services Centres (the "Director") issued a call for applications for new integrated community health services centre...

Recent developments in Ontario's health care system underscore the increasing complexity and risk associated with billing outside of the Ontario Health Insurance Plan (OHIP).

In the first half of 2025, the Rx IP Update team reported on a number of developments in Canadian life sciences IP and regulatory law. Below are our top stories.

On June 8, 2012, Genentech’s lawsuit seeking a declaration that US Patent No. 6,733,752 was invalid and not-infringed by Genentech’s trastuzumab product (HERCEPTIN).

Health Canada specifically contemplates certain proteins as SEBs in its Guidance, although Health Canada has not limited SEBs to only particular classes of drugs.

On May 23, 2012, the Federal Court held that Merck Frosst Canada Ltd. ("Merck") is liable to Apotex Inc. ("Apotex") for damages under section 8 of the Patented Medicines (Notice of Compliance) Regulations (the "Regulations"), but exercised its discretion to reduce the amount of compensation payable based on a defence of ex turpi causa.